Plain-English translation of NCT05562960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing plasmapheresis—a procedure that filters your blood to remove harmful antibodies—in people with ALS who have a specific autoantibody called anti-NRIP. Researchers believe this treatment might help slow down the disease in this particular group of patients by removing the antibodies that may be causing damage to nerve cells.
Some people with ALS have a specific antibody in their blood that appears to make their disease worse. This treatment aims to help this smaller group of patients by removing those harmful antibodies, which other treatments currently cannot do.
You likely qualify if…
You likely don't qualify if…
You would receive plasmapheresis treatments, which involve having your blood drawn, filtered through a machine to remove the harmful antibodies, and then returned to your body. You would attend multiple visits for these procedures and have regular blood tests and examinations to see how the treatment affects your symptoms and disease progression.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Taiwan
Sponsor
National Taiwan University Hospital
Enrollment target
~20 participants
Started
May 2023
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Li-Kai Tsai, MD, PhD
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.